Adamas Pharmaceuticals Inc.

4.62+0.1000+2.21%Vol 377.06K1Y Perf 49.67%
Apr 13th, 2021 14:30 DELAYED
BID4.60 ASK4.63
Open4.52 Previous Close4.52
Pre-Market4.50 After-Market-
 -0.02 -0.44%  - -
Target Price
8.25 
Analyst Rating
Moderate Buy 1.71
Potential %
78.57 
Finscreener Ranking
★★★+     51.87
Insiders Trans % 3/6/12 mo.
-67/-71/-71 
Value Ranking
★★     47.85
Insiders Value % 3/6/12 mo.
-47/-50/-50 
Growth Ranking
★★★+     55.98
Insiders Shares Cnt. % 3/6/12 mo.
-41/-47/-47 
Income Ranking
 —    -
Market Cap141.22M 
Earnings Rating
Sell
Price Range Ratio 52W %
32.59 
Earnings Date
6th May 2021

Today's Price Range

4.464.80

52W Range

2.439.15

5 Year PE Ratio Range

-4.90-1.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.50%
1 Month
-9.78%
3 Months
1.35%
6 Months
-7.19%
1 Year
49.67%
3 Years
-81.25%
5 Years
-74.62%
10 Years
-

TickerPriceChg.Chg.%
ADMS4.620.10002.21
AAPL134.463.22002.45
GOOG2 264.609.81000.44
MSFT258.202.29000.89
XOM55.630.13000.23
WFC39.78-0.9900-2.43
JNJ159.11-2.5300-1.57
FB312.330.79000.25
GE13.49-0.1000-0.74
JPM154.33-1.6200-1.04
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.20
0.87
6.80
-3.30
Leverage Ratio -3.50
ProfitabilityValueIndustryS&P 500US Markets
97.30
-66.80
-65.50
-5 429.90
-66.69
RevenueValueIndustryS&P 500US Markets
59.98M
1.33
171.46
181.32
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.53-0.64-20.75
Q03 2020-0.50-0.4216.00
Q02 2020-0.61-0.3739.34
Q01 2020-0.75-0.5921.33
Q04 2019-0.89-0.836.74
Q03 2019-0.90-0.99-10.00
Q02 2019-0.98-0.908.16
Q01 2019-1.13-1.084.42
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.49-8.89Negative
6/2021 QR-0.42-27.27Negative
12/2021 FY-1.57-17.16Negative
12/2022 FY-0.80-26.98Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.49
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume377.06K
Shares Outstanding30.57M
Trades Count1.57K
Dollar Volume24.37M
Avg. Volume692.43K
Avg. Weekly Volume253.15K
Avg. Monthly Volume324.27K
Avg. Quarterly Volume761.26K

Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) stock closed at 4.52 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 138.08K shares and market capitalization of 141.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 138 people. Adamas Pharmaceuticals Inc. CEO is Neil F. McFarlane.

The one-year performance of Adamas Pharmaceuticals Inc. stock is 49.67%, while year-to-date (YTD) performance is 4.39%. ADMS stock has a five-year performance of -74.62%. Its 52-week range is between 2.43 and 9.15, which gives ADMS stock a 52-week price range ratio of 32.59%

Adamas Pharmaceuticals Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 7.28, a price-to-sale (PS) ratio of 3.39, a price to cashflow ratio of 23.20, a PEG ratio of 2.32, a ROA of -38.71%, a ROC of -43.27% and a ROE of 225.34%. The company’s profit margin is -66.69%, its EBITDA margin is -65.50%, and its revenue ttm is $59.98 Million , which makes it $1.33 revenue per share.

Of the last four earnings reports from Adamas Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Adamas Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Adamas Pharmaceuticals Inc. is Moderate Buy (1.71), with a target price of $8.25, which is +78.57% compared to the current price. The earnings rating for Adamas Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamas Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamas Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.80, ATR14 : 0.51, CCI20 : -143.32, Chaikin Money Flow : -0.17, MACD : -0.19, Money Flow Index : 20.32, ROC : -9.96, RSI : 46.13, STOCH (14,3) : 8.91, STOCH RSI : 0.79, UO : 49.56, Williams %R : -91.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamas Pharmaceuticals Inc. in the last 12-months were: Christopher B. Prentiss (Sold 10 923 shares of value $55 753 ), David L. Mahoney (Option Excercise at a value of $31 920), John A. Macphee (Option Excercise at a value of $127 680), Spyridon Papapetropoulos (Buy at a value of $30 234), Vijay Shreedhar (Sold 5 565 shares of value $34 625 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
5 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Sell
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.71
Moderate Buy
1.71
Moderate Buy
1.71

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Neil F. McFarlane

Telephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, US

Number of employees: 138

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

Bearish Bullish

52%48%

News

Stocktwits